Hone Health raised $228 million for its virtual longevity clinic, with $200 million coming from General Catalyst’s Customer Value Fund and $28 million from a Series A equity extension led by MarcyPen Capital Partners, the company announced November 18.

Undiluted reports that the fund supplies money for sales and marketing, then takes payments tied to revenue from the customers that spending brings in. Hone did not disclose the arrangement’s price or repayment schedule.

Hone combines blood testing with physician consultations and ongoing treatment for hormone health, weight management and other conditions. Fierce Healthcare reported that an initial test covering 70 biomarkers costs $65, while a subscription costs $150 a month, plus medications.

At the time of its $33 million Series A in January 2025, Hone reported 55,000 patients treated. It now puts that cumulative figure above 200,000. The earlier round also funded its purchase of home care provider ivee, adding services such as blood draws at patients’ homes.

Co-founder and chief executive Saad Alam told Fierce Healthcare that Hone exceeded $100 million in revenue in 2025 and was on track to double that in 2026. He also said women’s services had overtaken men’s in net new members two months before the report, following Hone’s expansion beyond its initial hormone business.

Hone plans to use the financing to broaden clinical programs, add diagnostics including coronary CT angiography and expand the software physicians use to combine test results with medical histories. It also plans to build out clinical trial infrastructure to study patient outcomes.

Sources
1Hone Health financing announcement ↗
2Undiluted: financing structure and undisclosed terms ↗
3Fierce Healthcare: pricing and interview with Saad Alam ↗
4Hone Health’s earlier Series A and ivee acquisition ↗